This is a working overview of fatty diacid, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
The heart is the first functional organ to develop and starts to beat and pump blood at about three weeks into embryogenesis. This early start is crucial for subsequent embryonic and prenatal development. The heart derives from splanchnopleuric mesenchyme in the neural plate which forms the cardiogenic region. Two endocardial tubes form here that fuse to form a primitive heart tube known as the tubular heart. Between the third and fourth week, the heart tube lengthens, and begins to fold to form an S-shape within the pericardium. This places the chambers and major vessels into the correct alignment for the developed heart. Further development will include the formation of the septa and the valves and the remodeling of the heart chambers. By the end of the fifth week, the septa are complete, and by the ninth week, the heart valves are complete. Before the fifth week, there is an opening in the fetal heart known as the foramen ovale. The foramen ovale allowed blood in the fetal heart to pass directly from the right atrium to the left atrium, allowing some blood to bypass the lungs. Within seconds after birth, a flap of tissue known as the septum primum that previously acted as a valve closes the foramen ovale and establishes the typical cardiac circulation pattern. A depression in the surface of the right atrium remains where the foramen ovale was, called the fossa ovalis.
H2S. Very small amounts of H2S, SF6, and probably any other sulfur containing gases, cause immediate and complete deactivation of the catalyst. It is not possible to regenerate a poisoned catalyst that has been deactivated by sulfur, by treating with either oxygen or hydrogen. If sulfur containing gases are present in the sample, a switching valve should be used either to bypass the catalyst, or to back-flush the column to vent after elution of CO2. Air or O2. Reports of oxygen poisoning seem to be rather rumors than real facts. Small amounts of air through a catalyst will not kill it but anything over about 5 cc/min will cause an immediate and continual degradation of the catalyst. Unsaturated hydrocarbons. Samples of pure ethylene cause immediate, but partial, degradation of the catalyst, evidenced by slight tailing of CO and CO2 peaks. The effect of 2 or 3 samples might be tolerable, but since it is cumulative, such gases should be backflushed or bypassed. Low concentrations do not cause any degradation. Samples of pure acetylene affect the catalyst much more severely than does ethylene. Low concentrations have no effect. Probably some carbonization with high concentrations of unsaturates occurs, resulting in the deposit of soot on the catalyst surface. It is likely that aromatics would have the same effect. Other compounds. Water has no effect on the catalyst, as well as various Freons and NH3. Here again, with NH3, there is conflicting evidence from some users, who have seen a degradation after several injections, but other researchers were not able to confirm it.
From a scientific standpoint, it was a well characterized protein, whose structure had already been elucidated, making it easier to work with, in theory. Additionally, the widely available insulin at the time was pig insulin, and many people presented allergic reactions to this insulin. Human insulin, then, was preferable, for it was believed that people would not have allergic reactions to it. From a business standpoint, there was a large market for insulin; at the time, world sales were greater than $100 million, and growing. Boyer agreed that the insulin hormone should be their first target molecule. After concluding the market research, Swanson prepared Genentech's first business proposal by March 1976. It was with this proposal that Swanson pitched Genentech to Kleiner & Perkins. Perkins later explained that they considered the technical risks to be enormous: "(The risk of failure was) Very high. I figured better than 50–50 we'd lose it... (However) If it worked, the rewards would be obvious.". Boyer's scientific expertise and Swanson's business plan convinced the venture capitalists. While acknowledging the tremendous risk associated with the company, Kleiner and Perkins promised to invest $100,000 in Genentech. This was just a small fraction of Kleiner and Perkins's $8 million venture capital fund.
Flutamide has been found to be effective in the treatment of hirsutism (excessive body/facial hair growth) in numerous studies. It possesses moderate effectiveness for this indication, and the overall quality of the evidence is considered to be moderate. The medication shows equivalent or superior effectiveness to other antiandrogens including spironolactone, cyproterone acetate, and finasteride in the treatment of hirsutism, although its relatively high risk of hepatotoxicity makes it unfavorable compared to these other options. It has been used to treat hirsutism at dosages ranging from 62.5 mg/day to 750 mg/day. A study found that multiple dosages of flutamide significantly reduced hirsutism in women with polycystic ovary syndrome and that there were no significant differences in the effectiveness for dosages of 125 mg/day, 250 mg/day, and 375 mg/day. In addition, a study found that combination of 125 mg/day flutamide with finasteride was no more effective than 125 mg/day flutamide alone in the treatment of hirsutism. These findings support the use of flutamide at lower doses for hirsutism without loss of effectiveness, which may help to lower the risk of hepatotoxicity. However, the risk has been found to remain even at very low doses.
Sources: en.wikipedia.org
Playing Cards (French: Une partie de cartes, literally "A Card Party") is an 1896 French black-and-white silent actuality film by Georges Méliès. It was the first film in Méliès' prolific career, and thus is number one in his Star Film catalogue. It is a remake of Louis Lumière's film The Messers. Lumière at Cards, which was released earlier the same year. Along with Georges Méliès himself, his brother Gaston Méliès and daughter Georgette Méliès also appear in the film.
The dye was greatly prized in antiquity because the colour did not easily fade, but instead became brighter with weathering and sunlight. It came in various shades, the most prized being that of black-tinted clotted blood. Because it was extremely tedious to make, Tyrian purple was expensive: the 4th century BC historian Theopompus reported, "Purple for dyes fetched its weight in silver at Colophon" in Asia Minor. The expense meant that purple-dyed textiles became status symbols, whose use was restricted by sumptuary laws. The most senior Roman magistrates wore a toga praetexta, a white toga edged in Tyrian purple. The even more sumptuous toga picta, solid Tyrian purple with gold thread edging, was worn by generals celebrating a Roman triumph. By the fourth century AD, sumptuary laws in Rome had been tightened so much that only the Roman emperor was permitted to wear Tyrian purple. As a result, 'purple' is sometimes used as a metonym for the office (e.g. the phrase 'donned the purple' means 'became emperor'). The production of Tyrian purple was tightly controlled in the succeeding Byzantine Empire and subsidized by the imperial court, which restricted its use for the colouring of imperial silks. Later (9th century), a child born to a reigning emperor was said to be porphyrogenitos, "born in the purple". Some speculate that the dye extracted from the Bolinus brandaris is known as argaman (ארגמן) in Biblical Hebrew.
=== Breast feeding === Pantoprazole has been found to pass through the breast milk. Additionally, in rodent cancer studies, pantoprazole has been shown to potentially cause tumor growth. The clinical relevance of the finding is unknown, but risks and benefits are recommended for consideration in determining the use of therapy for the mother and child.
The new 16th district is entirely within El Paso County, taking in El Paso and such surrounding suburbs as Socorro, Horizon City, and Anthony. The incumbent is Democrat Veronica Escobar, who was re-elected with 59.5% of the vote in 2024. In 2024, Kamala Harris won 57.4% of the vote in this heavily Hispanic district, where Colin Allred also won with 58.4% of the vote.
=== Sphincters === The esophagus is surrounded at the top and bottom by two muscular rings, known respectively as the upper esophageal sphincter and the lower esophageal sphincter. These sphincters act to close the esophagus when food is not being swallowed. The upper esophageal sphincter is an anatomical sphincter, which is formed by the lower portion of the inferior pharyngeal constrictor, also known as the cricopharyngeal sphincter due to its relation with cricoid cartilage of the larynx anteriorly. However, the lower esophageal sphincter is not an anatomical but rather a functional sphincter, meaning that it acts as a sphincter but does not have a distinct thickening like other sphincters. The upper esophageal sphincter surrounds the upper part of the esophagus. It consists of skeletal muscle but is not under voluntary control. Opening of the upper esophageal sphincter is triggered by the swallowing reflex. The primary muscle of the upper esophageal sphincter is the cricopharyngeal part of the inferior pharyngeal constrictor. The lower esophageal sphincter, or gastroesophageal sphincter, surrounds the lower part of the esophagus at the gastroesophageal junction between the esophagus and the stomach. It is also called the cardiac sphincter or cardioesophageal sphincter, named from the adjacent part of the stomach, the cardia. Dysfunction of the gastroesophageal sphincter causes gastroesophageal reflux, which causes heartburn, and, if it happens often enough, can lead to gastroesophageal reflux disease, with damage of the esophageal mucosa.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.